Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 ?g per million cells in 100 ?l volume. It is recommended that the reagent be titrated for optimal performance for each application.

The DX5 clone detects cells expressing relatively high levels of CD49b and may not be useful for the detection of cells expressing low levels of CD49b. DX5 does not block NK cell killing or binding to collagen in vitro. Additional reported applications (for the relevant formats) include: complement-mediated cytotoxicity² and immunohistochemical staining⁵ of formalin-fixed and paraffin-embedded tissue sections as well as immunohistochemical staining of acetone-fixed frozen sections¹⁰. The binding of DX5 antibody to splenic NK cells can be blocked by HMa2 antibody.

1. Arase H, et al. 2001. J. Immunol. 167:1141. (FC)
2. Sepulveda H, et al. 1999. J. Immunol. 163:1133.
3. Norian LA and Allen PM. 2004. J. Immunol. 173:835. (FC)
4. Andoniou CE, et al. 2005. Nature Immunology 6:1011.
5. Oertelt S, et al. 2006. J. Immunol. 177:1655. (IHC) PubMed
6. Bourdeau A, et al. 2007. Blood doi:10.1182/blood-2006-08-044370.
7. Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
8. Qui Q, et al. 2010. J. Immunol. 184:1681. (FC) PubMed
9. Busche A, et al. 2011. J. Immunol. 186:2918. PubMed
10. Kim HR, et al. 2011. Nephrology 16:545. (IHC) PubMed
11. Seyoum B, et al. 2011. Vaccine. 29:8002. PubMed
12. Younos IH, et al. 2012. Int Immunopharmacol. 13:245. PubMed
13. Honjo K, et al. 2012. PNAS. PubMed.
14. Huang HN, et al. 2013. Biomaterials. 34:10151. PubMed

1. Bruce DW, et al. 2021. Blood Adv. 5:4578. PubMed
2. Wan Mohd Zawawi WFA, et al. 2021. Sci Rep. 11:10278. PubMed
3. Oertelt S, et al. 2006. J Immunol. 177:1655. PubMed
4. Wu L, et al. 2022. Front Immunol. 13:860761. PubMed
5. Arnold IC, et al. 2018. J Exp Med. 215:2055. PubMed
6. Tan L, et al. 2017. Int J Nanomedicine. 12:3095. PubMed
7. Si Y, et al. 2020. Sci Adv. 6:eaaw7713. PubMed
8. Blume J, et al. 2019. Eur J Immunol. 49:121. PubMed
9. Jogdand GM, et al. 2018. Front Immunol. 9:1041. PubMed
10. Kim O, et al. 2017. Nat Commun. 10.1038/s41467-017-00729-8. PubMed
11. McFarlane AJ, et al. 2017. J Allergy Clin Immunol. 140:1068. PubMed
12. Matsuba S, et al. 2017. Front Immunol. . 10.3389/fimmu.2017.01538. PubMed
13. Lim CS, et al. 2020. Front Immunol. 11:1186. PubMed
14. Yoon S, et al. 2020. Antioxidants (Basel). 10:. PubMed
15. Godoy-Calderón MJ, et al. 2018. Oncotarget. 8:11370. PubMed
16. Hu J, et al. 2019. Mol Ther Nucleic Acids. 16:650. PubMed
17. Blriot C, et al. 2021. Immunity. :. PubMed
18. Janela B, et al. 2019. Immunity. 50:1069. PubMed
19. Su S et al. 2018. Cell. 175(2):442-457 . PubMed
20. Brownlie D, et al. 2021. J Immunother Cancer. 9:. PubMed
21. Evrard M et al. 2018. Immunity. 48(2):364-379 . PubMed
22. Link CWM, et al. 2020. Front Immunol. 11:596772. PubMed
23. Gillory L, et al. 2013. PLoS One. 8:77753. PubMed
24. Busche A, et al. 2011. J Immunol. 186:2918. PubMed
25. Mizuno M, et al. 2021. Cancers (Basel). 13:. PubMed
26. Schnoegl D, et al. 2022. Front Immunol. 13:909270. PubMed
27. Lee YJ, et al. 2018. Front Microbiol. 9:83. PubMed
28. Hu X, et al. 2020. Neoplasia. 1.290972222. PubMed
29. Chen X, et al. 2012. Endocrinology. 153:4622. PubMed
30. Diao J, et al. 2018. J Immunol. 201:1306. PubMed
31. Huang H, et al. 2013. Biomaterials. 34:10151. PubMed
32. Leist SR, et al. 2019. PLoS One. 14:e0220126. PubMed
33. Seehus CR, et al. 2017. Nat Commun. 8:1900. PubMed

NK cells, subset of T cells

1. Arase H, et al. 2001. J. Immunol. 167:1141.
2. Barclay AN, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
3. Sasaki K, et al. 2003. Int. Immunol. 15:701.
4. Inoue O, et al. 2003. J. Cell Biol. 160:769.